Argentina’s president Javier Milei entered the campaign season defending his sister Karina after leaked recordings suggested bribery in state medicine contracts.
The case, now under court investigation, threatens his anti-corruption message and exposes the business stakes in Argentina’s vast pharmaceutical supply chain.
Federal Judge Sebastián Casanello ordered raids on the National Disability Agency (ANDIS) and private homes. He froze assets of former agency head Diego Spagnuolo, procurement officials, and executives of Suizo Argentina, a major medical supplier.
found executive Emmanuel Kovalivker with $266,000 in envelopes, while his brother Jonathan surrendered his phone after initially avoiding investigators.
The recordings attributed to Spagnuolo describe an alleged eight percent surcharge demanded from drug companies in exchange for state contracts. They mention Karina Milei and Eduardo “Lule” Menem, a presidential organizer. Both deny involvement.
Procurement data confirm Suizo Argentina’s government contracts rose sharply, from about 3.9 billion pesos in 2024 to roughly 108 billion pesos in 2025, after it secured a logistics role for medicine and vaccine deliveries.
That surge in state business put the company at the center of the scandal. The Milei government dismissed the accusations as a Kirchnerist ploy to destabilize ahead of elections.
At a rally in Junín, the president praised his sister and accused opponents of “sowing chaos.” A remark about “stealing their steals” drew widespread criticism online.
The case cuts deeper because ANDIS finances medicine and treatments for Argentines with disabilities and non-contributory pensions. Any diversion of funds undermines care for those who depend on public support.
The timing raises the stakes. Buenos Aires province, home to nearly four in ten Argentines, votes on September 7. National midterms follow October 26. The outcome will decide whether Milei can advance his economic agenda, even as his closest allies face legal scrutiny.
For international readers, the story matters because it shows how fragile anti-corruption platforms can become when campaign allies and family members face direct accusations.
It also highlights how lucrative public health contracts can fuel political battles in emerging markets, where billions in taxpayer funds depend on transparent oversight.